A’asPoint of care diagnostics for emerging markets.

Gold standard performance for 20X cheaper.No training or infrastructure required.

John died from a late TB diagnosis.1 of 150 million tests each year.

2

150 million TB tests per year means…

$300MM spent on TB testing

400K unnecessary deaths

$Billions direct, $10Bs indirect cost

750K work years lost from unnecessary travel

Only 60% of TB, 20% of MDR-TB is detected

$

3

Our device delivers diagnostics to the clinic.

Automated preparation

Single-use cartridges cost

$0.70 and sell for $2.50.

Innovative continuous-

flow microfluidics.

Sample goes in, result

comes out.

Android automatically collects data and trains technicians. No infrastructure required.

Optothermal PCR

Patent-pending tech

uses light-mediated

heating, enabling lower

cost, smaller cartridge,

faster testing & use

without infrastructure.

Mobile analysis

Mobile phone

components provide

fast & accurate

analysis, internet, and

software access.

4

And outperforms competition on every dimension.

Hardware cost Test cost Days before diagnosis Days traveling Error rate

A'as

GeneXpert

Smear (2 test)

$500 $2.50 30 min 0.5 3%

$18,000 $10.00 21 2 3%

$500 $3.00 42 2 30% 5

It’s based on new technology from Cornell.

Lab-quality performance at the POC for the first time.

Light focusing produces

heat exactly where it is

needed. Simple electronics,

sharp and well-defined heat

zones, lower power needs.

Continuous flow

microfluidic chip and

capillary pumping.

Sample-in, result-out

testing.

Mobile phone controls.

Easy to use,

automated operation

and data reporting.

1-step test Non-contact heating Mobile

6

Through low-cost, high-volume sales to govts & NGOs.

And can earn $1B revenue, save 1M lives. Yearly.

300K devices, 150K

locations

100K devices / year

$500 price

$500 cost

$50M @ 0% GP

200M replacement &

200M new tests per year

400M tests / year

$2.50 price

$0.70 cost

$1B @ 70% GP

1.5M users, 15K hospitals,

30 countries

Training for healthcare

workers, data for system

Variable

$50M @ 80% GP

7

3 funding stages: technology, market, scale.

0%

20%

40%

60%

80%

100%

Aug-14 Feb-15 Aug-15 Feb-16 Aug-16 Feb-17 Aug-17 Feb-18 Aug-18

Probability of A’as failure

$1 M Seed financing: build product, mitigate tech

risk

• Gather info from customer, grant-maker, user,

& supplier relationships; define product specs

• Build, test manufacturing prototype to specs

• Secure WHO GMP certification

• Secure manufacturing contracts

(Grant)

$5M Series A: prove business model, by closing

• Close first deals with 4 customer types: NGOs,

Private distributors, Private providers, Govts

• Demonstrate India, China demand

• First PoC device to market

• Clinical trial results

• Develop SaaS, new tests

$20M Series B: scale company

• Deploy SaaS, new tests globally

• Expand sales in India, China

8

And have laid the foundation for success.

Founding Team

Key Milestones

Onyx Adegbola, MD, PhD

GE Healthcare, Bayer Healthcare,

Novartis. MD from university of

Lagos, Pathobiology PhD @

Hopkins. Residency @ Columbia,

fellowships @ Penn & UCSF.

Li Jiang, PhD

PhD @ Cornell. Research in

mechanical & biomedical

engineering. Expertise in PCR,

microfluidics, microfabrication,

and product development.

Advisors:

William Bishai, MD PhD: World renowned TB expert @Johns Hopkins, Director K-RITH, HHMI Investigator

David Erikson, PhD: Co-inventor @ A’as. Leading microfluidics scholar. Co-founder @ Optofluidics, VitaMe.

Martha Li, PhD: former Senior Program Officer @ Gates Foundation, focus on biomarkers and diagnostics.

Lou Memoli, MS: medical device marketing, former business unit head @ Hitachi with $150MM P&L.

2 Key

Patents

Demonstrated

thermal stability,

Detection of 10

DNA /μL

Lab and Field

testing

9

We’re raising $1 million to go from prototype to product.

Use of funds Target specifications

10

11

Timeline and Exit Strategy

Step Timing

Incorporation and Planning 2014

Prototype 2015

Final Version / CE Mark/WHO prequalification 2016

Clinical Validation 2016

SolarDx Commercialization Commence activities 2015, first sales 2016

Potential acquisition through medical device companies

Timeline

Email oadegbola@aasinc.co for

more information.

www.aasinc.co

“If it works in Africa, it works

everywhere” - BRCK

12